Topics:

Ovarian Cancer

Ovarian Cancer

Maintenance therapy with the oral agent pazopanib improved progression free survival (PFS) by a median of 5.6 months in patients with advanced ovarian cancer but did not impact overall survival, according to the results of a phase III ran

The Society of Gynecologic Oncology (SGO) recently issued two new clinical practice statements recommending genetic testing for all women with endometrial and ovarian cancers, regardless of family history.

Being overweight increases a woman’s risk of ovarian cancer, according to a new comprehensive report. The finding offers a way to reduce the risk.

The use of oral contraceptives in women with BRCA1/2 mutations was associated with a reduced risk of ovarian cancer.

With regard to potential research strategies relevant to the treatment of triple-negative breast cancer/basal-like breast cancer, potential targets include PTEN, INPP4B, PIK3CA, KRAS, BRAF, EGFR, FGFR1, FGFR2, IGFR1, KIT, MET, PDGFRA, and the HIF1-α/ARNT pathway. Many of these will be discussed further in this review article.

The use of an enhanced recovery pathway for perioperative care in complex gynecological surgery can reduce length of hospital stay, need for narcotic pain control, and costs.

A new index using protein markers can identify ovarian cancer cases at high and low risk for recurrence and discriminate between short- and long-term survivors.

Pages

Subscribe to Ovarian Cancer on [sitename]

CME Center

Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.

By clicking Accept, you agree to become a member of the UBM Medica Community.